Cetirizine Hydrochloride Tablets USP 5 mg, 100-count bottle, Manufactured by: Unique Pharmaceuticals Labs, (A Div. of J.B. Chemicals & Pharmaceuticals, Ltd.), Mumbai 400 030, India. Distributed by: Rising Pharma Holdings, Inc., East Brunswick, NJ 08816, NDC 16571-401-10.
Published July 29, 2026 · Recall initiated: June 24, 2026
Summary
FDA records drug Class I recall D-0732-2026, published July 29, 2026 and initiated June 24, 2026. Recalling firm: JB Chemicals and Pharmaceuticals Ltd; Status: Ongoing; Reported quantity: 34,020 100-count bottles.; Lot: Lots: GY825029, GY825030, GY825031, GY825032, expires: 2028-OCT. Class I means a reasonable probability of serious adverse health consequences or death.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Cross Contamination with Other Products: Customer complaints for appearance of discolored tablets and red dots observed on Cetirizine Hydrochloride Tablets USP 5 mg. Determined to be Ranitidine.
What to do
Voluntary: Firm initiated · Letter
Get an email if CETIRIZINE HYDROCHLORIDE has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- CETIRIZINE HYDROCHLORIDE
- Manufacturer
- JB Chemicals and Pharmaceuticals Ltd
- Distributor
- Nationwide in the USA
- Lot
- Lots: GY825029, GY825030, GY825031, GY825032, expires: 2028-OCT
- Risk classification
- Class I
- Area (FDA)
- drug
- Country
- India
Related recalls
- FDAXylocaine (lidocaine HCl Injection, USP), 1%, 500 mg per 50 mL (10 mg per mL), 25 Multiple-Dose Vials, 50 mL,July 29, 2026
- FDADabigatran etexilate Capsules, 110 mg, 60-count carton (6x10), Rx Only, Manufactured by: Alkem Laboratories,July 29, 2026
- FDAXylocaine (lidocaine HCl Injection, USP), 1%, 200 mg per 20 mL (10 mg per mL), 25 Multiple-Dose Vials, 20 mL,July 29, 2026
- FDACetirizine Hydrochloride Tablets USP 10 mg, 100 Tablets bottles, Manufactured by: Unique Pharmaceuticals Labs,October 29, 2025
- FDACetirizine Hydrochloride Tablets USP 10 mg, 500 Tablets bottles, Manufactured by: Unique Pharmaceuticals Labs,October 29, 2025
- FDAChildren's Cetirizine HCl Chewable Tablets 5 mg, 30 count blister pack, Manufactured in India by SandozOctober 24, 2012
Questions about this recall
Was Cetirizine Hydrochloride Tablets USP 5 mg, 100-count bottle, Manufactured by: Unique Pharmaceuticals Labs, (A Div. of J.B. Chemicals & Pharmaceuticals, Ltd.), Mumbai 400 030, India. Distributed by: Rising Pharma Holdings, Inc., East Brunswick, NJ 08816, NDC 16571-401-10. recalled?
Yes. FDA published recall D-0732-2026 on July 29, 2026. Reported hazard: Cross Contamination with Other Products: Customer complaints for appearance of discolored tablets and red dots observed on Cetirizine Hydrochloride Tablets USP 5 mg. Determined to be Ranitidine.
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: CETIRIZINE HYDROCHLORIDE.